Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HCW Biologics ( (HCWB) ) has issued an announcement.
On June 17, 2025, HCW Biologics Inc. accepted the resignation of Gary M. Winer from its Board of Directors, with no immediate plans to fill his position. The resignation was not due to any disagreements with the company. During the same Annual Meeting, stockholders elected new Class I directors and ratified Crowe LLP as the independent accounting firm for the fiscal year ending December 31, 2025. Despite technical difficulties during the virtual meeting, a quorum was achieved, and the meeting was validly held. Broadridge Financial Solutions, the service provider, will send a letter to stockholders with a replay link and a platform for submitting questions.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.
HCW Biologics has a low overall stock score primarily due to its poor financial performance and valuation. While technical analysis reflects bearish momentum, recent corporate events provide a slight positive offset by showcasing investor interest and strategic partnerships. However, the financial instability and ongoing operational challenges remain significant concerns.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
Average Trading Volume: 684,959
Technical Sentiment Signal: Sell
Current Market Cap: $11.03M
For an in-depth examination of HCWB stock, go to TipRanks’ Overview page.